Trials / Completed
CompletedNCT00211419
Study of the Combination of Anecortave Acetate and Triamcinolone Acetonide for the Treatment of Exudative Age-Related Macular Degeneration (AMD)
Pilot Study of the Combination of Anecortave Acetate 15mg Delivered by Posterior Juxtascleral Injection and Triamcinolone Acetonide 4mg Delivered by Intravitreal Injection for the Treatment of Exudative Age-Related Macular Degeneration (AMD)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Manhattan Eye, Ear & Throat Hospital · Academic / Other
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety of combining juxtasclerally administered anecortave acetate 15 mg with triamcinolone acetate 4 mg administered intravitreally following photodynamic therapy with verteporfin for the treatment of exudative age-related macular degeneration (AMD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anecortave Acetate 15 mg | |
| DRUG | Triamcinolone Acetate 4 mg | |
| PROCEDURE | Photodynamic Therapy with Verteporfin | |
| PROCEDURE | Thermal Laser |
Timeline
- First posted
- 2005-09-21
- Last updated
- 2012-10-24
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00211419. Inclusion in this directory is not an endorsement.